GeneCopoeia Lentifect SARS-CoV-2 Spike-pseudotyped lentivirus

Saturday, 01 August, 2020 | Supplied by: United Bioresearch Products Pty Ltd

GeneCopoeia’s Lentifect SARS-CoV-2 Spike-pseudotyped lentivirus products are designed to produce a specially packaged variant of standard lentivirus that replaces VSV-G envelope glycoprotein with the Spike (S) protein.

The company’s spike-pseudotyped lentivirus can be used for several applications, such as: vaccine development for the SARS-CoV-2 virus; studying the efficacy and mechanism of neutralising antibodies against the SARS-CoV-2 virus; development of antiviral therapeutic agents; and studying the mechanism of virus-receptor interaction.

In addition to lentiviral particles, GeneCopoeia also offers a SARS-CoV-2 Spike Protein Pseudotyped Lentivirus Particle Kit that includes all required reagents: Lentifect SARS-CoV-2 Spike protein-pseudotyped lentiviral particles; Lentifect Standard VSV-G lentiviral particles; and the company’s ACE2-expressing HEK293T cell line.

For more information:

Phone: 02 4575 0309
Related Products

Promise Advanced Proteomics DIGESTIF tryptic digestion quality control

DIGESTIF is a generic standard designed to release indicators peptides which reflect the...

Exalpha Biologicals Recombinant Mouse anti-human CD56/NCAM antibody

The antibody has been validated for use in flow cytometry, immunocytochemistry and...

Biosensis Fluoro-Jade C (FJC) Powder for detecting neuronal degeneration

Fluoro-Jade C (FJC) from Biosensis stains all degenerating neurons regardless of specific insult...

  • All content Copyright © 2021 Westwick-Farrow Pty Ltd